Quantcast

Latest CEL-SCI Corporation Stories

2014-03-27 08:29:37

NEW YORK, March 27, 2014 /PRNewswire/ -- Across the globe, there are over 13 million new cancer cases each year. By 2030, it is estimated by the International Agency for Research on Cancer (IARC) that there will be approximately 21.4 million new cancer cases and 13.2 million cancer deaths worldwide. Some of the more common (and deadly) forms of cancer are head and neck cancer, which account for approximately 600,000 new cases worldwide each year and result in a five-year survival rate...

2014-03-10 16:31:52

Editor Note: For more information about this release, please scroll to bottom. LONDON, March 10, 2014 /PRNewswire/ -- On Friday, March 07, 2014, the US markets saw a mixed sentiment, with the NASDAQ Composite closing at 4,336.22, down 0.37%, the Dow Jones Industrial Average ending the session at 16,452.72, up 0.19% and the S&P 500 edging 0.05% higher to finish the trading session at 1,878.04. During the session gains in the Financials, Energy and Industrials sectors...

2014-01-27 08:27:11

NEW YORK, Jan. 27, 2014 /PRNewswire/ -- CEL-SCI Corporation (NYSE: CVM) is engaged in the research and development of drugs and vaccines. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia. CVM has products in stage 1 and 3 of the FDA approval process and the Multikine drug, has had promising results in Phase II and has the potential to treat multiple diseases. According to Market Line, by 2016, the global pharmaceuticals market is expected to have a...

2010-03-10 09:30:00

VIENNA, Va., March 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received a $125,000 payment from Byron Biopharma ("Byron") under its licensing agreement where CEL-SCI granted Byron an exclusive license to market and distribute the Company's cancer drug Multikine® in the Republic of South Africa (the "Territory"). CEL-SCI already has existing licensing agreements for Multikine with Teva Pharmaceuticals of Israel and Orient...

2010-02-22 08:45:00

VIENNA, Va., Feb. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model. The results were published in the scientific peer-reviewed Journal of International Immunopharmacology (online edition) in an article titled "CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease...

2010-02-17 08:00:00

VIENNA, Va., Feb. 17 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI Corporation (NYSE AMEX: CVM) to its shareholders: Dear Fellow Shareholders: We are pleased to report to you that the past 12 months have put CEL-SCI in the best position ever. During this difficult time we were able to complete and validate the manufacturing facility for our cancer drug Multikine, a critical step before being able to manufacture Multikine for the Phase III clinical trial. We...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related